Treatments compared for pediatric-onset multiple sclerosis

Summary by Ground News

More patients with POMS are free of new or newly enlarging lesions with dimethyl fumarate. The annualized relapse rate is lower with DMF, according to a study in JAMA. Suicide risk is highest in the first three months after the dementia diagnosis.

2 months ago·Billings, United States

News Articles

More Filters

All

Left

Center

Right

Medical Xpress

Treatments compared for pediatric-onset multiple sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.

2 months ago

Read Full Article

HealthDay

Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate

2 months ago

Read Full Article